What is Quantum Genomics?
Quantum Genomics is a Paris-based biopharmaceutical innovator established in 2005, dedicated to the development of a novel class of cardiovascular medications. The company's core scientific focus centers on brain aminopeptidase A inhibition (BAPAI), a pioneering approach designed to address unmet medical needs in hypertension and heart failure. By targeting the brain renin-angiotensin system, Quantum Genomics distinguishes itself from traditional therapeutic modalities, positioning its portfolio as a high-potential asset in the global life sciences market. The company operates at the intersection of advanced neurobiology and cardiology, aiming to redefine treatment standards for chronic cardiovascular conditions.
How much funding has Quantum Genomics raised?
Quantum Genomics has raised a total of $18.3M across 3 funding rounds:
Debt
$1.8M
Stock Offering
$16M
Other Financing Round
$539K
Debt (2021): $1.8M with participation from Bpifrance
Stock Issuance/Offering (2022): $16M, investors not publicly disclosed
Other Financing Round (2024): $539K, investors not publicly disclosed
Key Investors in Quantum Genomics
Bpifrance
Bpifrance is a French public investment bank that provides credit, guarantees, and equity to support companies across all stages of development. They specialize in fostering innovation and international expansion for startups, SMEs, and mid-cap enterprises.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Quantum Genomics?
With the recent strategic investment, Quantum Genomics is well-positioned to transition into its next phase of clinical development and commercial preparation. The focus will likely shift toward optimizing the delivery of its BAPAI-based therapies and expanding its footprint in international markets. Strategic priorities include the advancement of late-stage clinical trials and the strengthening of institutional partnerships to facilitate global distribution. As the firm matures, the emphasis on operational efficiency and data-driven clinical outcomes will be paramount in securing future growth and delivering value to stakeholders in the highly regulated biopharmaceutical sector.
See full Quantum Genomics company page
